



## Characterization, Pharmacology and *In-silico* study of 2,4 Diteriary Butylphenol Isolated from the leaves of *Ficus auriculata* Lour.

PRASHEENA RUSSELL. S<sup>1</sup> and PREMA KUMARI. J<sup>1\*</sup>

Department of Chemistry, Scott Christian College (Autonomous), Nagercoil-629003  
Affiliated to Manonmaniam Sundaranar University, Tirunelveli, India.

\*Corresponding author E-mail: premaisaac67@gmail.com

<http://dx.doi.org/10.13005/ojc/390122>

(Received: October 28, 2022; Accepted: January 01, 2023)

### ABSTRACT

*Ficus auriculata* belongs to the family of dicotyledonous plant. The general phytochemical screening for Ethanol, Hexane, Chloroform and Water extracts are done. Since ethanol shows the presence of maximum compounds, it is subjected to the isolation of phenolic compounds by TLC and Column Chromatography. On repeating this process, a white crystalline solid results, which on the basis of UV-Vis, FT-IR, GC-MS, <sup>1</sup>H NMR, confirms that the isolated compound is 2,4 Diteriary Butyl Phenol (2,4 DTBP). The isolated compound is further studied for its solvent effect and subjected to anti-microbial and Cytotoxicity studies with AGS cancer cell line and HIEC-6 (Human Normal Intestinal Epithelial cell line). Docking studies is carried out using PatchDock server, with 2,4 DTBP as guest and Occludin, which is a Tight Junction Protein (TJP) as host. The resulted structure is further subjected to Lipinski Rule of five. The present study concludes that 2,4 DTBP shows intermediate resistance against *Gram-positive* and *Gram-negative* bacteria like *S. aureus*, *E. coli*, *Klebsiella pneumonia*, strongly resistant to fungi *Candida sps*. According to cytotoxic and *In silico* studies, the isolated compound has excellent anticancer properties and is thus used in the treatment of gastric cancer. From the Lipinski rule, it is confirmed that the drug can be administered orally.

**Keywords:** *Ficus auriculata*, Phytochemicals, Isolation, 2,4 Diteriary ButylPhenol, Pharmacology, *In-silico* studies, Gastric cancer.

### INTRODUCTION

Medicinal plants act as a natural resource, providing opportunities for the discovery of new drugs. Plants used in traditional medicine contains a variety of substances that can be used for healing chronic and infectious diseases. Thousands of phytochemicals from plants are

safer than other effective methods with minimal side effects.<sup>1</sup> Phytochemicals, commonly referred to as secondary metabolites, produced by plants through several chemical methods can be beneficial in the function of human cells.<sup>2</sup> Polyphenols exhibit many protective functions such as hypolipidemic, antiproliferative, anti-inflammatory and antioxidative effects which



reduce the onset of the disease.<sup>3</sup> Extraction is a very important step in analyzing existing nutrients plant.<sup>1</sup> *Ficus auriculata* is a small, perennial evergreen tree which is cultivated in South and Southeast Asia and Brazil for its edible fruits.<sup>4</sup> There are few studies on the benefits of *F. auriculata* to human health due to its phytochemical compounds.<sup>5</sup> 2,4-DTBP was also reported in different groups of plants, like *Phaeodactylum tricornutum* Bohlin (diatom), *Marchantia polymorpha* L (liverwort), *Osmunda regalis* L and *Adiantum venustum* D (ferns).<sup>6</sup> It has been reported that 2,4-Di-tert-butylphenol exhibit moderate cytotoxicity against HeLa and MCF-7, high percentage of antioxidant, anti-bacterial activity and induces senescence in human gastric adenocarcinoma.<sup>7,18</sup> A global issue in the field of surgery is postoperative wound infections, which are linked to prolonged hospital stays. An infection in the tissues around the incision and the surgical site is referred to as a postoperative wound infection, and it typically develops five to thirty days following surgery. *Streptococcus species*, *Proteus species*, *Enterobacter species*, *Klebsiella species*, *Coagulase negative* and *Pseudomonas species*, are the most common pathogen.<sup>8</sup>

The effects of several solvents (including ethanol, water, butanol, ether, hexane, carbon tetrachloride, and chloroform) on 2,4-DTBP using UV-Vis spectra were taken into consideration.

The findings revealed that the UV region experienced majority of absorptions, and that the primary electronic transitions are connected to  $n-\sigma^*$  and  $\sigma-\sigma^*$ . The absorption values in different solvents are influenced by dielectric constants of the solvents. The solvent polarizability tends to move the absorption maximum towards lower wavelength.<sup>9</sup> Molecular docking studies predict the preferred orientation of one molecule to another when they are bonded together to form a stable complex.<sup>20</sup> The objective is to determine the correct interaction between two molecules.<sup>10</sup> Lipinski's rule of five, which has been used for nearly 20 years as a broad "rule of thumb" for valuing drug-like qualities, is a widely used way

to forecast a drug's performance, mostly for oral medications.<sup>11</sup>

The focus of my work is to identify the Phytochemicals present in various solvents, Isolation of bioactive phenolic component 2,4-Di-tert-butylphenol, its Characterization using various spectral analysis, and study the effect of various solvents using UV-Vis spectra. The compound is also tested for its anti-microbial activity, cytotoxicity and its drug-likeness is evaluated by in-silico study.

## MATERIALS AND METHODS

Plant leaves were collected from Nagercoil locality, washed well with double distilled water, shadow dried for 3-4 weeks, powdered and preserved for further work. Plant authentication was done by Dr. M. U Sharief, Scientist 'E' & Head of Office, Botanical Survey of India, Southern Regional Centre, Coimbatore. The voucher specimen no. BSI/SRC/5/23/2021/Tech-263.

### Materials required

Ethanol, Chloroform, Hexane, Water, Lead Acetate, Neutral  $\text{FeCl}_3$ , Fehling Solution (A & B), 4% NaOH, 1%  $\text{CuSO}_4$ , Acetic acid, Wagner Reagent, Dil.HCl, Conc. $\text{H}_2\text{SO}_4$ , Distilled water.

### Preparation of extracts

The powdered plant material (5 g) is extracted with solvents (500 mL) like Ethanol, Hexane, Chloroform, Water using Soxhlet apparatus for 24 hours. The solvent is evaporated using rotary evaporator.

### Phytochemical Analysis Isolation of Phenolic compound Column Fractions

Silica gel (mesh size 230-400) is used in column chromatography. The column is packed using wet packing method, washed with Ethyl acetate solvent. The plant extract is loaded into the packed column. Ethyl acetate: Hexane (30:70) is used as the eluent, the extract is eluted and the fractions were collected in vials. This is further subjected to TLC.<sup>12</sup>

Test	Observation	Inference
About 1 mL of the extract is shaken with 1 mL of Lead acetate solution	Formation of white precipitate	Presence of Tannin.
About 1 mL of the extract is shaken vigorously with water and warmed	Formation of foam	Presence of Saponin.
About 1 mL of extract is shaken with distilled water and Neutral FeCl <sub>3</sub> .	Formation of dark green colour	Presence of Phenolic compounds
Fehling's Test: 1 mL of extract is mixed with 1 mL Fehling A & 1 mL Fehling B solution. This is mixed and boiled.	Formation of brick red precipitate	Presence of Carbohydrate.
Biuret Test: About 1 mL of extract is shaken with 4% NaOH and 1% CuSO <sub>4</sub> solution	Formation of violet or pink colour	Presence of Protein.
About 1 mL of the extract is shaken with CHCl <sub>3</sub> , Conc. H <sub>2</sub> SO <sub>4</sub> and Acetic acid.	Formation of green colour	Presence of Steroids.
About 1 mL of extract is shaken with neutral FeCl <sub>3</sub> . To the extract, about 2 mL of glacial acetic acid in 1 drop FeCl <sub>3</sub> is added	Formation of brown colour Formation of brown colour	Presence of Flavonoids. Presence of Cardiac glycoside.
About 1 mL of the extract, is shaken with 1 mL of 10% NaOH.	Formation of yellow colour	Presence of Coumarin compounds.
To the extract add dil. HCl. Filter this and add Wagner Reagent (I <sub>2</sub> in KI) to the filtrate.	Formation of Reddish brown precipitate	Presence of Alkaloids.

### Thin Layer Chromatography

TL Cready-madesheet (Silicagel 60 F25420 cmx20 cm) is cut in to equal sizes and thin mark of 0.5 cm was made from the bottom to load the sample spots. Ethyl acetate: Hexane (6:14) is used as the mobile phase. The TLC sheet prepared is placed in the beaker containing the mobile phase. It is removed after the sample spot is raised above the level in mobile phase. This is dried, and placed under Iodine chamber and examined under UV for various spots. From the spot R<sub>f</sub> value can be calculated by the formula.

### R<sub>f</sub>=Distance travelled by the solute/Distance travelled by the solvent. Gas chromatography-Mass spectrometry (GC-MS)

The JEOL GC-MATE II GC-MS with Data system, a high resolution, double focusing instrument, was used to conduct the GC-MS analysis. 6000-pixel maximum resolution maximum calibrated mass: 1500 Dalton on a capillary column (300.25 mL D 0.25 mm) fused to an Elite-5MS (5% diphenyl/95% dimethyl poly siloxane). Utilizing the data bases of the National Institute of Standards and Technology (NIST) and Wiley Spectra Libraries, the interpretation of the mass spectrum GC-MS was carried out. The name of the molecule was determined using the molecular weight, molecular formula, and the number of hits from the NIST and Wiley spectral libraries.<sup>13</sup>

### HPLC

HPLC is recorded using SHIMADZU, LC-10AT VP, at ANJAC, Sivakasi.

### UV-Vis Spectroscopy

The UV absorption spectra is recorded using systronics smart double beam spectrophotometer-2203, in Scott Christian College, Nagercoil.

### FT-IR Spectroscopy

The FT-IR is recorded using Shimadzu FT-IR Spectrometer, in ANJAC, Sivakasi.

### <sup>1</sup>H-NMR

<sup>1</sup>H-NMR spectroscopy was carried out using Bruker 300MHz FTNMR Spectrometer, in Gandhi Gram Rural University, Dindugal.

### Anti-microbial activity of 2,4 DTB Anti-bacterial activity Sample Preparation Test Organism

The given sample was dissolved in a mixture of aqueous and ethanol solvents at a concentration of 0.1 g/1 mL.

Clinical samples were used to isolate *Staphylococcus aureus*, *E. coli*, *Klebsiella pneumoniae*, *Enterococcus faecalis*, *Bacillus subtilis*, and *Pseudomonas aeruginosa* to study their antimicrobial properties.

The lack of zone inhibition was taken to mean that there was no activity. When the zone of inhibition is smaller than 7mm, the activities are classified as resistant moderate 8–10mm, and sensitive greater than 11mm.<sup>14-16</sup>

### Anti-fungal activity Test Organism

The test Fungi used *Candida sp* is isolated from the environment for antifungal analysis. Antifungal assays performed by disc diffusion method.<sup>17</sup>

### MTT Assay Principle

MTT Assay Utilises cellular metabolic activity as a gauge of cell viability, proliferation, and cytotoxicity. This colorimetric assay relies on the transformation of purple formazan crystals to methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or MTT) by metabolically active cells. The MTT is converted to formazan by NAD(P)H-dependent oxidoreductase enzymes found in live cells.<sup>21</sup> An ELISA plate reader is used to measure the absorbance at 570nm after the insoluble formazan crystals have been dissolved using a solubilizing solution (100% DMSO).

The cytotoxic effect of the isolated compound is tested in both HIEC-6 (Human Normal Intestinal Epithelial cell line) and Gastric Adenocarcinoma (AGS) cell lines.

All experiments were carried out in triplicates. The cell viability is determined using the following formula:

$$\text{Percentage of cell viability} = \frac{\text{Average absorbance of treated}}{\text{Average absorbance of control}} \times 100$$

### IC<sub>50</sub> value

The sample's half maximal inhibitory concentration is known as the IC<sub>50</sub> value. The average absorbance of the various concentrations of the test sample (6.25-100 g/mL) were plotted in Microsoft Excel, and the equation for slope ( $y=mx+C$ ) was derived.

### Molecular Docking Studies

The 3D structural data of 2,4 DTBP was obtained from PubChem database in SDF format, it is translated into PDB format using PYMOL software and the 3D structural data of Occludin, a Tight Junction (TJ) protein is obtained from Protein Data Bank using

the search interface. Using the Patch Dock server, the 2,4 DTBP ligand and Occludin, the receptor molecule, are uploaded along with the 3D coordinate data file in order to dock the guest 2,4 DTBP into the cavity of the host Occludin. Each conformation is given a docking score by the Patch Dock server.

### Lipinski Rule of Five

Lipinski rule of 5 helps is used to distinguish the drug like and non-drug likeness of molecules. Lipinski's rule states that, an orally active drug should not violate more than one of the following criteria:

- Molecular mass <500 Dalton
- Lipophilicity (LogP<5)
- Hydrogen Bond Donors <5
- Hydrogen Bond Acceptors <10
- Molar Refractivity ~40-130

## RESULTS AND DISCUSSION

Table 1 shows the column fractions eluted using various solvents like Methanol: Chloroform, Ethyl acetate: Hexane in various ratios.

**Table 1: Column fraction eluted**

S.No	Solvent system	Ratio	Volume	Fractions
1	Methanol:Chloroform	4:16	20	6
2	Ethyl acetate:Hexane	5:95	100	5
3	Ethyl acetate:Hexane	6:14	20	7

Table 2 shows the TLC of solvents Methanol: Chloroform and Ethyl acetate: Hexane in various ratios. Out of which Fraction IV is subjected to further evaluation.

**Table 2: Thin Layer Chromatography using solvents of various ratios**


S.No	Solvent system	Ratio	Volume(mL)	No of Spots
1	Methanol:Chloroform	4:16	20	No spot
2	Ethyl acetate:Hexane	1:19	20	No spot
3	Ethyl acetate: Hexane	2:18	20	4
4	Ethyl acetate:Hexane	4:16	20	4
5	Ethyl acetate:Hexane	6:14	20	3
6	Ethyl acetate:Hexane	8:12	20	No spot

Table 3 shows the phytochemicals present in various solvents, from the above data, it is concluded that, Ethanol is the most preferred solvent, since it shows the presence of majority of the components.

**Table 3: Phytochemicals present in various solvents**


Phytochemical constituent	Ethanol	Hexane	Chloroform	Water
Tannin	+	-	-	-
Phenolic Compound	+	-	-	-
Protein	-	-	+	+
Flavonoids	+	-	+	+
Cardiac Glycoside	+	-	+	+
Coumarin	+	+	-	-
Saponin	+	+	-	-
Alkaloids	+	-	+	+
Carbohydrate	+	-	+	+
Steroid	+	+	+	-

### Structural elucidation of the Isolated compound GC-MS of Fraction IV

**Fig. 1. GCMS Spectra of the isolated compound**


The isolated compound's molecular mass is determined to be 206.32 from the  $m/z$  value.

### HPLC

**Fig. 2. HPLC spectra of purity of the isolated compound**


The retention time of 2,4 DTBP isolated from the ethanolic extract of *Ficus auriculata* leaves was about 3.077.

### UV-Visible Spectroscopy

**Fig. 3. UV-Visible Spectra of the isolated compound**

The UV-Visible spectra of the isolated compound is performed over a wavelength range of 200-800nm. Tertiary butyl group absorbs in the range 224nm and 276.8nm with intensities at 1.273 and 0.75 respectively. This indicates the presence of phenolic functional group. These data provides additional support to the structure.

### FT-IR Spectroscopy

**Fig. 4. IR Spectra of the isolated compound**

The IR Spectrum of the compound isolated shows various peaks. Out of which, O-H stretching is represented by  $3519.85\text{ cm}^{-1}$ , C-H stretching is represented by  $2962.46\text{ cm}^{-1}$ , C-C stretching of aromatic compounds is represented by  $1506.30\text{--}1604.66\text{ cm}^{-1}$ , C-H bending in the tertiary butyl group may be responsible for  $1362.61\text{ cm}^{-1}$ , and C-O stretching frequency is represented by  $1252.68\text{ cm}^{-1}$ . Based on all these data, it is clear that the isolated compound contains aromatic ring, tertiary butyl group and phenolic group. Hence the compound may be 2,4 Ditertiary Butyl Phenol.

### $^1\text{H}$ Nuclear Magnetic Resonance ( $^1\text{H}$ NMR) Spectroscopy



Fig. 5. <sup>1</sup>H-NMR Spectra of the isolated compound

Figure 5 shows the <sup>1</sup>H NMR spectra of the compound isolated. The signals revealed the presence of phenolic proton (D) at 3.376, Methylene proton (R-CH<sub>2</sub>-R) (F) at 1.232, Methine proton (R<sup>3</sup>C-H) (E) at 1.348 and aromatic protons (A) (B)&(C) around 7.147, 7.141 and 7.006 respectively.

The existence of each of these signals supports the isolated compound's structure.

The Phytochemical screening, Column Fractions, TLC Studies, GC-MS Spectra, UV-Vis, FT-IR and <sup>1</sup>H NMR confirms that the isolated compound is 2,4-DTBP and its structure is.



### Effect of Solvent

Name of Bacteria Strains	Samples Zone of inhibition (mm in diameter)					
	S1 25µg	S1 50µg	S1 75µg	S1 100µg	Positive control	Negative control
<i>E. coli</i> (G-)	9	10	10	11	16	-
<i>Staphylococcus aureus</i> (G+)	-	-	8	9	16	-
<i>Enterococcus faecalis</i> (G+)	-	-	-	-	17	-
<i>Pseudomonas aeruginosa</i> (G-)	-	-	-	-	10	-
<i>Klebsiella pneumoniae</i> (G-)	8	11	12	14	20	-

The anti-bacterial activity of 2,4 DTBP was analyzed with various bacteria like: *E. coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*.




Fig.6. Effect of Solvent on the isolated compound

The solvent effects on the electronic absorption is used to identify the electronic transitions in a molecule. The light absorbed by the compound shifts from low energy, long wavelength to high energy, short wavelength as the solvents become more polar.

**Table 4: Effect of Solvent on the isolated compound**

Solvent	Wavelength	Absorbance
Water	221.6	1.237
Ethanol	224	1.273
Ether	231.2	1.351
Butanol	224	1.282
Chloroform	243.2	1.512
Carbon tetrachloride	243.2	1.515
Hexane	219.2	1.122

Figure 6 & Table 4 shows the Effect of Solvent on the isolated compound. Saturated compounds with one hetero atom (ethanol, butanol, ether, CCl<sub>4</sub>, CHCl<sub>3</sub>, water) undergoes n → σ\* transition, whereas in Hexane only sigma bond is available and hence σ → σ\* transition occurs, which requires higher energy and lower wavelength.

### Anti-microbial property of 2,4 DTBP

**Table 5: Anti-Bacterial activity of 2,4 DTBP**

Name of Bacteria Strains	Samples Zone of inhibition (mm in diameter)					
	S1 25µg	S1 50µg	S1 75µg	S1 100µg	Positive control	Negative control
<i>E. coli</i> (G-)	9	10	10	11	16	-
<i>Staphylococcus aureus</i> (G+)	-	-	8	9	16	-
<i>Enterococcus faecalis</i> (G+)	-	-	-	-	17	-
<i>Pseudomonas aeruginosa</i> (G-)	-	-	-	-	10	-
<i>Klebsiella pneumoniae</i> (G-)	8	11	12	14	20	-

*Enterococcus faecalis*, *Pseudomonas aeruginosa* has no inhibition. *E. coli*, *Staphylococcus aureus*, *Klebsiella pneumoniae* shows inhibition. Out of these three, *Klebsiella pneumoniae* shows higher

inhibition than *E. coli*, *Staphylococcus aureus*. Hence it is concluded that, 2,4 DTBP strongly inhibits the activity of bacteria *Klebsiella pneumonia*.




Fig. 7. Anti-bacterial activity of the isolated compound on (a) *E. coli* (b) *Staphylococcus aureus* (c) *Enterococcus faecalis* (d) *Pseudomonas aeruginosa* (e) *Klebsiella pneumonia*

Table 6: Anti-Fungal activity of 2,4 DTBP

Fungal name	Samples Zone of inhibition(mm in diameter)					
	S1 25µg	S1 50µg	S1 75µg	S1 100µg	Positive control	
<i>Candida sps</i>	6	10	11	12	14	-

Figure 8 depicts the anti fungal activity of the compound isolated, 2,4 DTBP with *Candida albicans*. This fungi shows dense zone of inhibition. The compound is very active against the fungi.



Fig. 8. Anti-fungal activity of the compound isolated on *Candida albicans*

### Cytotoxic Effect MTT Assay

Table 7: % cell viability values of 2,4 DTBP against HIEC-6 cells after the treatment period of 24 hours

Culture condition	%cell viability	IC <sub>50</sub> conc. (µg/mL)
Untreated	100	
Std control (Dox-5µM)	56.20	
S1-10µg/mL	99.41	NA
S1-25 µg/mL	94.89	
S1-50 µg/mL	89.08	
S1-75 µg/mL	78.87	
S1-100 µg/mL	69.50	




Fig. 9. %cell viability values 2,4 DTBP against HIEC-6 cells after the incubation period of 24 hours





Fig. 10. Effect of Concentration of isolated compound on HIEC-6 cells (a) untreated (b) 10 µg/mL (c) 25 µg/mL (d) 50 µg/mL (e) 75 µg/mL (f) 100 µg/mL

Figure 9 is the graphical representation of the viability of HIEC-6 cells with the isolated compound, and Fig.10 shows the effect of concentration of the isolated compound on HIEC-6 cells.


The observed results clearly confirmed the Non-toxic efficacy of the isolated compound on Normal human intestinal epithelial cells with % cell viability value of 69%, at the highest concentration of 100  $\mu\text{g/mL}$  after the incubation period of 24 hours.

**Table 8: Cell Viability of AGS cells with 2,4DTBP at various concentrations**

Samples	Triplicate 1	Triplicate 2	Triplicate 3	Average	Percentage of Viability	IC <sub>50</sub>
Control	0.679	0.668	0.653	0.66667	-	83.18
6.25	0.633	0.625	0.617	0.625	93.75	
12.5	0.584	0.571	0.565	0.57333	86	
25	0.495	0.486	0.477	0.486	72.9	
50	0.395	0.416	0.407	0.406	60.9	
100	0.287	0.305	0.313	0.30167	45.25	



**Fig. 11. Cell Viability of AGS cellline with isolated compound**




**Fig. 12. Effect of Concentration of isolated compound on AGS cellline (a) untreated (b) 6.25  $\mu\text{g/mL}$  (c) 12.5  $\mu\text{g/mL}$  (d) 25  $\mu\text{g/mL}$  (e) 50  $\mu\text{g/mL}$  (f) 100  $\mu\text{g/mL}$**

Figure 11 is the graphical representation of the viability of AGS Cell line with the isolated compound, and Fig. 12 shows the effect of concentration of the isolated compound on AGS cellline. As the concentration increases, the viability decreases. At 100  $\mu\text{g/mL}$  concentration, the viability of the cancer cell is minimum. (ie):45.25%.

With varied quantities of the sample supplied to SKMEL cancer cells, a dose-dependent reduction in cell viability was seen. 83.18  $\mu\text{g/mL}$  is the IC<sub>50</sub> value obtained for the sample.

### Molecular Docking Study



**Fig. 13. 3-D Structure of (a) 2,4 DTBP (b) Occludin (c) 2,4DTBP Docked with Occludin**

Figure 13 (a),(b) shows the 3-D structures of 2,4 DTBP, Occludin respectively. These structures are obtained in PDB format and view using PyMol software. Out of all the models, the one with score 2846 for the area 358.70 is chosen as the most favourable model, which is represented in Fig. 11(c).



**Table 9: Set of PatchDock results showing the docking structures of Occludin with 2,4 DTBP**

S. No	Score	Area	Atomic Contact Energy(ACE)	Transformation
1	2846	358.70	-57.23	-3.021.14 -1.87 6.06 15.72 0.80
2	2828	352.50	-101.00	0.081.24 -2.43 2.85 14.97 8.88
3	2790	331.70	-84.85	-0.49-1.03 0.30 2.75 14.84 9.02
4	2726	366.90	14.29	1.290.07 3.07 6.43 18.21 -6.28
5	2696	314.20	-73.90	-2.03-0.33 2.07 3.83 13.90 7.91
6	2684	368.00	7.26	-1.450.19 0.04 7.3618.54 -6.72
7	2680	304.10	-24.97	-1.67-0.35 1.68 1.29 12.73 17.69
8	2666	306.10	-1.60	-0.05-1.20 1.94 9.92 20.16 -14.58
9	2646	345.80	-18.61	-2.090.07 2.79 8.0016.19 -2.19
10	2632	372.20	-61.13	0.64-1.12 1.99 6.4816.07 -0.33

**Lipinski Rule of Five****Table 10: Lipinski Rule for 2,4 DTBP with Occludin**

Mass	206
Hydrogen Bond Donor	1
Hydrogen Bond Acceptor	1
Log P	3.987
Molar Refractivity	65.506

From the above results, it is clear that the compound 2,4 DTBP doesn't violate any criteria, hence it can be orally administered.

Phytochemicals present in various extracts of *Ficus auriculata* leaf has been analyzed. From the Chromatographic, GC-MS and Spectroscopic studies, and comparing the results from various literatures, it is found that the isolated compound is 2,4 Ditertiary Butyl phenol, which is biologically active compound, and from the *In vitro* & cytotoxicity studies, it is found to possess anti-microbial & anti-cancer activity. The 3-D structure obtained from Molecular docking studies, is subjected to Lipinski rule of 5, and from the data obtained it can be concluded that 2,4 DTBP can be administered orally.

**CONCLUSION**

Phytochemicals present in various extracts of *Ficus auriculata* leaf has been analyzed.

**ACKNOWLEDGEMENT**

The authors wish to thank the corresponding institutions for their instrumental support.

**REFERENCES**

- Sasidharan, S.; Chen, Y.; Saravanan, D.; Sundram, K.M.; Yoga Latha, L. *Afr. J. Complement Altern Med.*, **2011**, *8*(1), 1–10.
- Sunyoung Yoo.; Kwansoo Kim.; Hojung Nam.; Doheon Lee. *Nutr.J.*, **2018**, *10*(8), 1042.
- Swapna Upadhyay.; Madhulika Dixit. *Oxid. Med. Cell. Longev.*, **2015**, 1-15.
- Vinay Kumar.; Nirmal Kumar.; Leirika Ngangom.; Kunal Sharma.; Manu Pant.; Syed Mohsin Waheed., *Eco. Env. & Cons.*, **2020**, *26*(October Suppl. Issue), 108-113.
- Luísa Lima Bertolotti.; Everton Skoronski.; Liziane Schittler Moroni.; Aniela Pinto Kempka. *Agric. Conspec. Sci.*, **2020**, *85*(4), 303-310.
- Fuqiang Zhao.; Ping Wang.; Rima, D.; Lucardi.; Zushang Su.; Shiyu Li. *Toxins.*, **2020**, *12*(35), 1-26.
- Ei Aung.; Alfinda Novi Kristanti.; Nanik Siti Aminah.; Yoshiaki Takaya.; Rico Ramadhan., *Ecol. Environ. Sci.*, **2020**, *5*(4), 2573-2919.
- Reiye Esayas Mengesha.; Berhe Gebre-Slassie Kasa.; Muthupandian Saravanan.; Derbew Fikadu Berhe.; Araya Gebreyesus Wasihun., *BMC Res. Notes.*, **2014**, *7*, 575.
- Fatimah Abdulsayid, A.; Hamad Adress Hasan, M. *Int. J. Innov. Sci. Eng. Technol.*, **2020**, *7*(5), 78-85.
- Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G., *J Mol Biol.*, **1996**, *261*(3), 470-489.
- Thomas Karami, K.; Shumet Hailu.; Shaoxin Feng.; Richard Graham.; Hovhannes Gukasyan, J., *J Ocul Pharmacol Ther.*, **2022**, *38*(1), 43-55.

12. Soo Jung Choi.; Jae Kyeom Kim.; Hye Kyung Kim.; Keith Harris.; Chang-Ju Kim.; Gwi Gun Park.; Cheung-Seog Park.; Dong-Hoon Shin. *J. Med. Food.*, **2013**, *16*(11), 977-983.
13. Mihaela Pana.; Alexandru Pana.; Gabriella Rau.; George Dan Mogosanu., *Farmacia.*, **2011**, *59*(6), 830-841.
14. Kohner, P. C.; Rosenblatt, J. E.; Cockerill, F. R. *J. Clin. Microbiol.*, **1994**, *32*, 1594-1596.
15. Mathabe, M.C.; Nikolova, R.V.; Lall, N.; Nyazema, N. Z. *J. Ethnopharmacol.*, **2006**, *105*, 286-293.
16. Assam, A. J. P.; Dzoyem J. P, Pieme, C. A.; Penlap V. B. *BMC Complement. Altern. Med*, **2010.**, *10*(40), 1-7.
17. Bauer, A. W.; Kirby, W. M. M.; Sherris, J. C.; Turck M. Amer. I. *C/in. Pathol.*, **1966**, *45*, 493-496.
18. Yeon Woo Song.; Yoongho Lim.; Somi Kim Cho. *BBAMCR.*, **2018**, *18241*, 1-36.
19. Young-MinKim.; In-HyeKim.; Taek-Jeong. *Mol. Med. Rep.*, **2013**, *8*, 11-16.
20. Lengauer, T.; Rarey, M. *Curr. Opin. Struct. Biol.*, **1996**, *6*(3), 402-406.
21. Mosmann, T., *J. Immunol. Methods.*, **1983**, *65*(1-2), 55-63.